Sort   by:  
 Page size 
UnknownPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Not available
S-EPMC3157979 | biostudies-literature
UnknownPhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Not available
S-EPMC4534525 | biostudies-literature
UnknownTBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Not available
S-EPMC8462533 | biostudies-literature
UnknownGenomic Characterization of de novo Metastatic Breast Cancer.
Not available
S-EPMC7887078 | biostudies-literature
UnknownPhase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Not available
S-EPMC7607628 | biostudies-literature
UnknownSafety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Not available
S-EPMC6219487 | biostudies-literature
UnknownTumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC7269810 | biostudies-literature
UnknownPredicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Not available
S-EPMC12597502 | biostudies-literature
UnknownSafety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Not available
S-EPMC12205636 | biostudies-literature
UnknownEffect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Not available
S-EPMC7489368 | biostudies-literature
Sort   by:  
 Page size